🇺🇸 FDA
Pipeline program

SAGE-718

718-CNA-201

Phase 2 small_molecule completed

Quick answer

SAGE-718 for Alzheimer Disease is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
SUPERNUS PHARMACEUTICALS, INC.
Indication
Alzheimer Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials